|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
lumbar puncture
adult patients
pediatric patients
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:M09AX07
|
|
gptkbp:CASNumber
|
1258984-36-9
|
|
gptkbp:chemicalClass
|
antisense oligonucleotide
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Biogen
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:firstApprovedIndication
|
spinal muscular atrophy
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
loading and maintenance doses
|
|
gptkbp:genericName
|
gptkb:nusinersen
|
|
gptkbp:halfLife
|
135-177 days (CSF)
|
|
gptkbp:hasMolecularFormula
|
C234H324N61O128P17S17
|
|
gptkbp:hasSMILES
|
not applicable (oligonucleotide)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Spinraza
|
|
gptkbp:indication
|
treatment of 5q spinal muscular atrophy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
antisense oligonucleotide
|
|
gptkbp:orphanDrugStatus
|
yes
|
|
gptkbp:patent
|
gptkb:Biogen
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
intrathecal injection
|
|
gptkbp:sideEffect
|
fever
nausea
respiratory infection
constipation
headache
back pain
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:nusinersen
|
|
gptkbp:target
|
gptkb:SMN2_gene
|
|
gptkbp:therapeuticArea
|
neurology
|
|
gptkbp:usedFor
|
spinal muscular atrophy
|
|
gptkbp:bfsParent
|
gptkb:Biogen
gptkb:Zolgensma
|
|
gptkbp:bfsLayer
|
5
|